LRRK2 is a large molecular machine involved in organizing materials inside cells. It is found in the brain as well as in immune cells, the lungs and the kidneys, where it performs functions that are not yet fully understood. The protein contains seven distinct domains, including regions that bind other cellular components and two enzymatic units. One of these enzymes is a kinase, which modifies target proteins by attaching phosphate groups to them. Excessive phosphorylation by LRRK2 is associated with Parkinson’s-related cellular dysfunction.

A second enzymatic region acts as a molecular switch by binding either GTP or GDP. In many cellular signaling proteins, GTP binding corresponds to an active state, while conversion of GTP to GDP helps return the protein to an inactive state. LRRK2, however, is controlled by a more intricate relationship between its switch and kinase domains. The Weill Cornell team set out to determine how these regions communicate and how their interaction controls access to the kinase’s active site.

Using cryo-electron microscopy alongside biochemical experiments, the researchers captured LRRK2 in a broad collection of structural states. They examined 16 different configurations, including molecules bound to GTP, molecules bound to GDP and molecules carrying neither nucleotide. These snapshots allowed the investigators to reconstruct the protein’s movements as it transitions between inactive and active forms, much like assembling a molecular film from individual frames.

The structures showed that GDP plays a central role in restraining LRRK2. When GDP is bound, LRRK2 adopts a compact conformation in which several domains fold toward one another and obstruct the kinase active site. This arrangement prevents the kinase from effectively contacting its protein targets. When GDP is released, the molecule undergoes a substantial rearrangement. Its domains move apart, exposing the active site and allowing the kinase to phosphorylate other proteins. Binding of GTP can then help stabilize this active configuration.

“This work provides a platform for identifying molecules that promote the formation of one configuration or the other,” said Dr. Samara Reck-Peterson, chair and professor of biochemistry and biophysics at Weill Cornell Medicine and an investigator at the Howard Hughes Medical Institute. Such compounds could allow researchers to control LRRK2 by influencing its overall shape rather than simply blocking the catalytic site. That approach may be especially valuable because LRRK2 carries out normal functions in several organs, making broad suppression potentially undesirable.

The structural data also clarified how Parkinson’s-associated mutations activate LRRK2 through different mechanisms. One well-known mutation occurs directly within the kinase domain and can increase the enzyme’s catalytic performance. Other mutations are located far from the kinase active site, including near the GTP-GDP switching machinery. Rather than making the kinase intrinsically faster, these distant mutations appear to increase the amount of time LRRK2 spends in its active conformation.

That distinction could have important consequences for treatment design. A drug that blocks the kinase’s catalytic pocket may work against mutations that directly enhance enzymatic activity, but it may not fully address mutations that alter the protein’s switching behavior. In the latter cases, an allosteric drug—one that binds at a regulatory site away from the active center—could potentially shift LRRK2 toward its inactive architecture. “Such allosteric drugs may offer greater precision and fewer side effects than conventional kinase inhibitors,” said Dr. Andres Leschziner, professor of biochemistry and biophysics at Weill Cornell and co-lead investigator.

The findings arrive as LRRK2 inhibitors and related compounds move through clinical testing, with at least four trials underway. The new structural blueprint could help medicinal chemists design therapies that selectively stabilize the off state or prevent disease-linked mutations from prolonging the on state. The study, led by Weill Cornell researchers with collaborators at the University of California, San Francisco, and Goethe University in Frankfurt, was co-first-authored by graduate students Amalia Villagran Suarez and Kathryn Hatch. By showing precisely how LRRK2’s domains cooperate to control its activity, the work brings researchers closer to mutation-specific strategies for slowing Parkinson’s disease while preserving the protein’s normal biological roles.

Subject of Research: LRRK2 protein activation and autoinhibition in Parkinson’s disease

Article Title: The structural basis for LRRK2’s activation and autoinhibition

News Publication Date: 10-Aug-2026

Web References: https://doi.org/10.1016/j.cell.2026.07.027; https://vivo.weill.cornell.edu/display/cwid-slr4003; https://vivo.weill.cornell.edu/display/cwid-ale4009

References: Cell, DOI: 10.1016/j.cell.2026.07.027

Image Credits: Weill Cornell Medicine

Keywords: Parkinson’s disease, LRRK2, protein structure, cryo-electron microscopy, kinase activity, GTP-GDP switch, molecular biology, allosteric drugs, neurodegenerative disease, biomedical research

Parkinson’s disease is a multifaceted neurodegenerative disorder affecting millions globally. Traditionally, Parkinson’s diagnosis has rested on clinical symptoms such as bradykinesia, tremors, and rigidity. Yet, despite this seemingly unified clinical presentation, the disease’s underlying genetic architecture is strikingly diverse. Numerous genetic mutations have been implicated in Parkinson’s, each potentially disrupting distinct molecular pathways. This genetic and molecular complexity has long impeded the development of universally effective treatments, as therapies effective for one pathway might fail for another.

The research team, led by Professor Patrik Verstreken at the VIB-KU Leuven Center for Neuroscience, highlighted the critical need to reconceptualize Parkinson’s not as a monolith but as a spectrum of related disorders with unique molecular underpinnings. Through their machine-learning-driven analysis leveraging fruit fly models engineered to carry mutations across 24 different Parkinson’s-associated genes, the team captured nuanced behavioral phenotypes that reflect molecular dysfunction. This approach diverges dramatically from conventional hypothesis-driven studies, offering an unbiased lens into the disease’s complexity.

A crucial feature of this study lies in its methodology. Rather than assuming how specific gene mutations might influence the disease phenotype, researchers monitored the behavior of these genetically diverse flies longitudinally. Advanced computational models and unsupervised machine learning algorithms were then employed to detect latent structures within the dataset. This unbiased analysis allowed distinct molecular forms of Parkinsonism to be classified naturally, revealing patterns invisible to traditional analytical frameworks.

According to first author Dr. Natalie Kaempf, this data-centric approach was paramount in uncovering the disease’s hidden stratification. The team observed that the behavioral manifestations of the various genetic mutations coalesced into two broad subtypes, which could further be parsed into five detailed subgroups. This granular classification marks the first comprehensive attempt to molecularly dissect Parkinson’s using behavioral outputs from an animal model, opening transformative possibilities in understanding and treating the disease.

The implications of these findings extend beyond academic curiosity. Professor Verstreken emphasized that clinicians typically view Parkinson’s disease through the lens of shared clinical symptoms, which obscures the molecular diversity underlying these presentations. Recognizing distinct molecular subtypes is clinically significant because it underscores why a one-size-fits-all drug approach has been largely unsuccessful. Instead, this research paves the way for tailored treatments targeting the specific molecular dysfunctions inherent to each Parkinson’s subgroup.

In a proof-of-concept demonstration, the researchers tested pharmacological compounds on their fly models stratified by the identified subtypes. Remarkably, a compound that effectively reversed Parkinsonian phenotypes in one subgroup did not yield benefits in another, underscoring the necessity for subtype-specific therapeutic development. This paradigm shift suggests that future clinical trials will need to incorporate molecular stratification to accurately evaluate drug efficacy.

Beyond Parkinson’s disease, this unbiased, machine-learning-based framework holds profound potential for other genetically heterogeneous conditions. Diseases caused by diverse mutations or complex environmental interactions might similarly benefit from such data-driven subclassifications. This integrative approach could revolutionize how we categorize and ultimately treat many complex disorders by revealing biologically meaningful subtypes invisible to traditional methods.

Moreover, the study underscores the transformative power of machine learning in biomedical research. By letting data patterns emerge organically without imposing preconceived hypotheses, researchers can uncover previously hidden disease structures. This innovation not only deepens biological understanding but also accelerates precision medicine by identifying clinically actionable targets closely aligned with molecular pathology.

The VIB-KU Leuven team envisions that the next steps will involve translating these discoveries into clinical practice. By pinpointing biomarkers pertinent to each molecular Parkinson’s subtype, physicians could diagnose patients more accurately and tailor interventions that offer maximal therapeutic benefit. This proactive stratification strategy promises to enhance treatment outcomes, reduce side effects, and ultimately improve quality of life for patients worldwide.

This study, published on 10 March 2026, stands as a testament to the synergy between advanced computational techniques and traditional experimental biology. By harnessing the sophisticated behavioral phenotyping of Drosophila models combined with machine learning, the researchers provide a robust template for future investigations into neurodegenerative diseases and beyond.

In summary, this monumental research redefines Parkinson’s disease as a constellation of molecularly distinct entities rather than a single disorder. It highlights the futility of universal treatments and propels the field toward precision therapeutics. Most importantly, it illuminates a path where cutting-edge computational tools and experimental rigor converge to solve some of the most complex puzzles in human health.

Subject of Research: Animals

Article Title: Behavioral screening defines the molecular Parkinsonism-related subgroups in Drosophila.

News Publication Date: 5 May 2026

Web References:

• DOI: 10.1038/s41467-026-70303-8

Keywords: Neuroscience, Cell biology, Molecular biology, Diseases and disorders